Document:

exv10w29

 

EXHIBIT 10.29

LIMITED WAIVER

TO

LOAN AND SECURITY AGREEMENT

AND AMENDMENT NO. 3
 

     This Limited Waiver to Loan and Security Agreement and Amendment No. 3 (this
“Waiver”) is entered into this 9th day of May, 2007, by and among PlanetOut Inc., a
Delaware corporation (“PlanetOut”), PlanetOut USA Inc. , a Delaware corporation
(“PlanetOut USA”), LPI Media Inc., a Delaware corporation (“LPI”), SpecPub, Inc.,
a Delaware corporation (“SpecPub”), RSVP Productions, Inc., a Delaware corporation
(“RSVP”), (PlanetOut, PlanetOut USA, LPI, SpecPub, and RSVP are collectively referred to herein as
the “Borrowers” and individually as a “Borrower”), and ORIX Venture Finance LLC
(“Lender”). Capitalized terms used herein without definition shall have the same meanings given
them in the Loan Agreement (as defined below).

Recitals

     A.     Borrowers and Lender have entered into that certain Loan and Security Agreement dated as of
September 28, 2006, as amended by Amendment No. 1 to Loan and Security Agreement and Pledge
Agreements dated as of November 8, 2006, and Amendment No. 2 to Loan and Security Agreement
(“Amendment No. 2”) dated as of February 14, 2007 (as may be amended, restated, or otherwise
modified, the “Loan Agreement”), pursuant to which the Lender has agreed to extend and make
available to Borrower certain advances of money.

     B.     Borrowers have failed to achieve the Minimum EBITDA and Liquidity covenants set forth in
Section 6.7 of the Loan Agreement as of March 31, 2007 and the Liquidity covenant as of April 30,
2007 (together, the “Existing Defaults”), and have notified Lender that they expect to fail to
achieve the Liquidity covenant as of May 31, 2007 (the “May Liquidity Test”).

     C.     Borrowers desire that Lender waive the Existing Defaults and the May Liquidity Test upon
the terms and conditions more fully set forth herein.

     D.     Subject to the representations and warranties of Borrowers herein and upon the terms and
conditions set forth in this Waiver, Lender is willing to provide the limited waiver and amendment
contained herein.

Agreement

       NOW, THEREFORE, in consideration of the foregoing Recitals and intending to be
legally bound, the parties hereto agree as follows:

     1.     Financial Covenants.   Borrowers acknowledge their failure to achieve Minimum
EBITDA for the period tested as of March 31, 2007 as provided for in Section 6.7(a) of the Loan
Agreement (the “EBITDA Event”) and Minimum Liquidity as provided for in Section 6.7(b) of the Loan
Agreement for the periods tested as of the end of each of the months of March and April 2007 (the “Liquidity Events”).
Borrowers further request that Lender waive compliance by Borrowers with the May Liquidity Test.

 

 

     2.     Limited Waiver.   Lender hereby agrees, subject to the terms of Section 3 hereof,
to waive (i) the EBITDA Event, (ii) the Liquidity Events and (iii) the May Liquidity Test. Lender
further agrees, subject to the terms of Section 3 hereof, to waive any misrepresentation in Section
3(c) of Amendment No. 2 in connection with Borrowers’ failure to disclose the amendment to
PlanetOut’s certificate of incorporation filed January 8, 2007.

     3.      Conditions to Limited Waiver.

          3.1      Engagement of Investment Bankers.   Not later than May 15, 2007, Borrowers shall have
engaged an investment banking firm for the purpose of raising capital for PlanetOut, and shall have
provided evidence of the same to Lender.

          3.2      Establishment of Lockbox.   Not later than May 18, 2007, Borrowers shall have established a
lockbox account with a bank to which Account debtors shall be directed to make payment and into
which the proceeds of all Accounts shall be deposited, pursuant to a blocked account agreement in
such form as Lender may reasonably specify.

          3.3      Term Sheet for Capital Event.   Not later than June 8, 2007, Borrowers shall have received
a signed term sheet, reasonably satisfactory to Lender, from one or more investors for the issuance
of new equity or subordinated debt in an aggregate gross amount of not less than $15,000,000 (the
“Capital Event”).

          3.4      Capital Event Closings.   Not later than June 30, 2007, Borrowers shall have (i) obtained a
written commitment from one or more investors in the form of one or more subscription or purchase
agreements to purchase new equity or subordinated debt issued by PlanetOut in at least the gross
amount of $15,000,000, subject only to customary closing conditions, including shareholder approval
as may be required, and (ii) closed the issuance of new equity of at least 3,500,000 shares of
common stock (on an as-converted basis in the case of convertible subordinated debt) or
subordinated debt for gross proceeds of not less than $7,000,000 (the “Initial Capital Raise”) and
received the proceeds thereof, of which $1,500,000 shall be immediately remitted to Lender for
application to amounts due under the Term Loan, in inverse order of maturity. Not later than
August 31, 2007, Borrowers shall have closed the issuance of new equity or subordinated debt
resulting in gross proceeds of at least an amount equal to $15,000,000 less the amount of gross
proceeds from the Initial Capital Raise, and shall have received the proceeds thereof, of which an
additional $1,500,000 (for a total of $3,000,000) shall be immediately remitted to Lender for
application to amounts due under the Term Loan, in inverse order of maturity.

          3.5      No Prepayments of Indebtedness.   Other than Indebtedness incurred pursuant to the Loan
Agreement, Borrowers shall not pay any Indebtedness, including without limitation, the LPI Notes,
prior to its due date.

          3.6      Payment of Success Fee.  In the event a Change in Control of PlanetOut occurs, and Lender
consents to such Change in Control in accordance with the Loan Agreement, Borrowers shall pay to Lender
immediately upon the closing of such Change in Control a fee in the amount of $250,000.

2

 

     4.      Amendments.

          4.1      Term Loan Interest.   The first sentence of Section 2.2.1 to the Loan Agreement (Interest
Rates) is deleted and replaced in its entirety by the following: “Borrowers shall pay interest to
Lender in arrears on each applicable Interest Payment Date, at the following rates: (a) with
respect to the Advances, each Advance shall bear interest on the outstanding principal amount
thereof from the date when made until paid in full at a rate per annum equal to the Base Rate plus
one percent (1.0%), and (b) with respect to the Term Loan, the Term Loan shall bear interest on the
outstanding principal amount thereof from the date when made until paid in full at a rate per annum
equal to the Base Rate plus five percent (5.00%).”

          4.2      Minimum Cash.   A new Section 6.7(c) is added to the Loan Agreement as follows: “Minimum
Cash. Borrowers shall maintain at all times cash and cash equivalents in an amount not less than
$4,500,000 through June 30, 2007, $7,000,000 from July 1 through July 31, 2007, and $3,000,000
commencing August 1, 2007.”

     5.      Borrowers’ Representations And Warranties.   Each Borrower represents and
warrants that:

               (a)      immediately upon giving effect to this Waiver (i) the representations and warranties
contained in the Loan Documents are true, accurate and complete in all material respects as of the
date hereof (except to the extent such representations and warranties relate to an earlier date, in
which case they are true and correct as of such date), and (ii) no Event of Default has occurred
and is continuing;

               (b)      such Borrower has the corporate power and authority to execute and deliver this Waiver and
to perform its obligations under the Loan Agreement, as amended by this Waiver;

               (c)      except for the amendment to the certificate of incorporation of PlanetOut in January 2007
(a copy of which has been delivered to Lender), the certificate of incorporation, bylaws and other
organizational documents of such Borrower delivered to Lender on the Closing Date remain true,
accurate and complete and have not been amended, supplemented or restated and are and continue to
be in full force and effect;

               (d)      the execution and delivery by such Borrower of this Waiver and the performance by such
Borrower of its obligations under the Loan Agreement as amended by this Waiver have been duly
authorized by all necessary corporate action on the part of such Borrower;

               (e)      this Waiver has been duly executed and delivered by the Borrowers and is the binding
obligation of each Borrower, enforceable against it in accordance with its terms, except as such
enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or
other similar laws of general application and equitable principles relating to or affecting
creditors’ rights; and

3

 

               (f)      as of the date hereof, it has no defenses against the obligations to pay any amounts under
the Obligations. Each Borrower acknowledges that Lender has acted in good faith and has conducted
in a commercially reasonable manner its relationships with Borrowers in connection with this Waiver
and in connection with the Loan Documents.

          Each Borrower understands and acknowledges that Lender is entering into this Waiver in
reliance upon, and in partial consideration for, the above representations and warranties, and
agrees that such reliance is reasonable and appropriate.

     6.      Limitation.   The waiver and amendments set forth in this Waiver shall be limited
precisely as written and shall not be deemed (a) to be a waiver or modification of any other term
or condition of the Loan Agreement or of any other instrument or agreement referred to therein or
to prejudice any right or remedy which Lender may now have or may have in the future under or in
connection with the Loan Agreement or any instrument or agreement referred to therein; or (b) to be
a consent to any future amendment or modification or waiver to any instrument or agreement the
execution and delivery of which is consented to hereby, or to any waiver of any of the provisions
thereof. Except as expressly waived and amended hereby, the Loan Agreement and each of its terms
and conditions shall continue in full force and effect.

     7.      Effectiveness.   This Waiver shall become effective upon the satisfaction of all
the following conditions precedent:

          7.1      Waiver.  Borrowers and Lender shall have duly executed and delivered this Waiver to
Lender.

          7.2      Payment of Lender Expenses.   Borrowers shall have paid all Lender Expenses (including all
reasonable attorneys’ fees and reasonable expenses) incurred through the date of this Waiver.

     8.      Release.  In further consideration of Lender’s execution of this Waiver, each
Borrower for itself and on behalf of its successors (including, without limitation, any trustees
acting on behalf of Borrower and any debtor-in-possession with respect to Borrower), assigns,
subsidiaries and affiliates, hereby forever releases Lender and its successors, assigns, parents,
subsidiaries, affiliates, officers, employees directors, agents and attorneys (collectively, the
“Releasees”) from any and all debts, claims, demands, liabilities, responsibilities, disputes,
causes, damages, actions and causes of action (whether at law or in equity) and obligations of
every nature whatsoever, whether liquidated or unliquidated, known or unknown, matured or
unmatured, fixed or contingent (collectively, “Claims”), that Borrower may have against the
Releasees that arise from or relate to any actions which the Releasees may have taken or omitted to
take prior to the date this Waiver was executed, including without limitation with respect to the
Obligations, any Collateral, the Loan Agreement, any other Loan Document and any third parties
liable in whole or in part for the Obligations, other than arising out of Lender’s gross negligence
or willful misconduct. This provision shall survive and continue in full force and effect whether
or not Borrower shall satisfy all other provisions of this Waiver, the Loan Agreement or the other
Loan Documents, including payment in full of all Obligations.

4

 

     9.      Indemnities.   Each Borrower hereby agrees that its obligation to indemnify and
hold the Releasees harmless as set forth in the Loan Agreement shall include an obligation to
indemnify and hold the Releasees harmless with respect to any and all liabilities, obligations,
losses, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or
nature whatsoever incurred by the Releasees, or any of them, whether direct, indirect or
consequential, as a result of or arising from or relating to any proceeding by, or on behalf of,
any Person, including, without limitation, officers, directors, agents, trustees, creditors,
partners or shareholders of any Borrower, whether threatened or initiated, asserting any claim for
legal or equitable remedy under any statute, regulation or common law principle arising from or in
connection with the negotiation, preparation, execution, delivery, performance, administration and
enforcement of this Waiver or any other document executed in connection herewith, other than
arising out of such Releasees’ gross negligence or willful misconduct. The foregoing indemnity
shall survive the payment in full of the Obligations and the termination of this Waiver, the Loan
Agreement and the other Loan Documents.

     10.      Counterparts.   This Waiver may be signed in any number of counterparts, and by
different parties hereto in separate counterparts, with the same effect as if the signatures to
each such counterpart were upon a single instrument. All counterparts shall be deemed an original
of this Waiver.

     11.      Integration.   This Waiver and any documents executed in connection herewith or
pursuant hereto contain the entire agreement between the parties with respect to the subject matter
hereof and supersede all prior agreements, understandings, offers and negotiations, oral or
written, with respect thereto and no extrinsic evidence whatsoever may be introduced in any
judicial or arbitration proceeding, if any, involving this Waiver; except that any financing
statements or other agreements or instruments filed by Lender with respect to Borrowers shall
remain in full force and effect.

     12.      Governing Law; Venue.   THIS WAIVER SHALL BE GOVERNED BY AND SHALL BE CONSTRUED
AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA. Borrowers and Lender each
submit to the exclusive jurisdiction of the State and Federal courts in San Francisco County,
California.

[signature page follows]

5

 

     In Witness Whereof, the parties have duly authorized and caused this Waiver to be
executed as of the date first written above.

BORROWERS:

	 	 	 
	PlanetOut Inc.	 	LPI Media Inc.
	 
	 	 
	 
	 	 
	 
	 	 
	By: /s/ Daniel J. Miller                              

	 	By:/s/ Daniel J. Miller                              
	 
	 	 
	Name: Daniel J. Miller

	 	Name: Daniel J. Miller
	 
	 	 
	Title: Senior Vice President, Chief
Financial
Officer and Treasurer

	 	Title: Chief Financial Officer
	 

	 	Address and facsimile number for notices:
	 
	 	 
	Address and facsimile number for notices:
	 	 
	 
	 	 
	 c/o
PlanetOut Inc.

	 	c/o PlanetOut Inc.
1355 Sansome Street
	1355 Sansome Street

	 	San Francisco, CA 94111
	San Francisco, CA 94111

	 	Attn: Todd Huge
	Attn: Todd Huge

	 	fax: (415) 834-6378
	fax: (415) 834-6378
	 	 
	 
	 	 
	 
	 	 
	SpecPub, Inc.

	 	RSVP Productions, Inc. 
	 
	 	 
	 
	 	 
	By:/s/ Daniel J. Miller                              

	 	By:/s/ Daniel J. Miller                              
	 
	 	 
	 
	 	 
	Name: Daniel J. Miller

	 	Name: Daniel J. Miller
	 
	 	 
	Title: Chief Financial Officer

	 	Title: Chief Financial Officer
	 
	 	 
	Address and facsimile number for notices:

	 	Address and facsimile number for notices:
	 
	 	 
	c/o PlanetOut Inc.

	 	c/o PlanetOut Inc.
	1355 Sansome Street

	 	1355 Sansome Street
	San Francisco, CA 94111

	 	San Francisco, CA 94111
	Attn: Todd Huge

	 	Attn: Todd Huge
	fax: (415) 834-6378

	 	fax: (415) 834-6378

6

 

	 
	PlanetOut USA Inc.
	 

	 

	By:/s/ Daniel J. Miller                              

	 

	Name: Daniel J. Miller

	 

	Title: Chief Financial Officer

	 

	Address and facsimile number for notices:

	 

	c/o PlanetOut Inc.

	1355 Sansome Street

	San Francisco, CA 94111

	Attn: Todd Huge

	fax: (415) 834-6378

7

 

LENDER:

ORIX Venture Finance LLC

	 
	By:/s/ Kevin P. Sheehan                              

	 

	Name: Kevin P. Sheehan

	 

	Title: President & CEO

	 

	Address and facsimile number for notices:

	 

	ORIX Venture Finance LLC,

	245 Park Avenue, 19th Floor

	New York, NY 10167-0001

	Attn: Kevin Sheehan

	Fax: (212) 497-7917

With a copy to:

ORIX Venture Finance LLC,

151 Lytton Avenue, Palo Alto,

CA 94301,

Attention: Mr. Michael David.

Fax: (650) 617-0706

8exv10w25

 

Exhibit 10.25

LICENSE AGREEMENT

     This License Agreement (the “Agreement”) is entered into as of April 18, 2007 between
DermaVentures, LLC an Illinois limited liability company with its principle place of business at
440 S. LaSalle St., Suite 3400, Chicago, IL 60605 (“Licensee”) and Helix BioMedix, Inc., a Delaware
corporation with its principle place of business at 22118 20th Avenue SE, Suite 204, Bothell, WA
98021 (“Licensor”).

RECITALS

     WHEREAS, Licensee was formed on December 21, 2006 for the purpose, without limitation, of
marketing and selling skin care products;

     WHEREAS, RMS Group, LLC, an Illinois limited liability company (“RMS”) and Licensor
are the sole members of DermaVentures, LLC and are bound by the terms and conditions of that
certain Operating Agreement of DermaVentures, LLC dated as of January 31, 2007 (the
“DermaVentures LLC Agreement”);

     WHEREAS, Licensee, Licensor, and RMS are parties to a Management Services Agreement of even
date herewith (the “Management Agreement”) that specifies certain management services that
Licensor will provide and imposes certain terms and conditions on the parties thereto in connection
with the operation and management of Licensee under the DermaVentures LLC Agreement; and

     WHEREAS, the parties wish to enter into this Agreement to provide for the license by Licensor
to Licensee of certain technology.

AGREEMENT

     1. Certain Definitions.

          1.1 An “Affiliate” of a party means an entity directly or indirectly controlling, controlled
by or under common control with that party, where control means the ownership or control, directly
or indirectly, of more than 50% of all of the voting power of the shares (or other securities or
rights) entitled to vote for the election of directors or other governing authority, as of the date
of this Agreement or hereafter during the term of this Agreement; provided that such entity shall
be considered an Affiliate only for the time during which such control exists.

          1.2 “Disclosing Party” means a party hereto that discloses its Proprietary Information to the
other party.

          1.3
 ***.

* * * Confidential treatment requested

 

 

          1.4 “Peptide(s)” means Licensor’s proprietary bioactive peptide(s) described in Exhibit
A.

          1.5 “Product” means the final, marketable cosmetic or over-the-counter personal care
formulations incorporating Peptide(s) that are set forth in Exhibit B. Additional Products
may be added to Exhibit B by agreement of the parties.

          1.6 “Proprietary Information” of a Disclosing Party means the following, to the extent
previously, currently or subsequently disclosed to the other party hereunder or otherwise:
information relating to the properties, composition, or structure of technology or the manufacture
or processing thereof or machines therefor or to the Disclosing Party’s business (including,
without limitation, names and expertise of employees and consultants, know-how, formulas,
processes, ideas, inventions (whether patentable or not), schematics, and other technical,
business, financial, customer and product development plans, forecasts, strategies and
information). In particular, but without limitation, the Peptides and their properties,
composition, or structure, and the Technology, are Proprietary Information of Licensor.

          1.7 “Proprietary Rights” means patent rights, copyrights, trade secret rights and all other
intellectual and industrial property rights of any sort.

          1.8 “Receiving Party” means a party hereto that receives Proprietary Information of the other
party.

          1.9 “Technology” means inventions (whether or not patentable), ideas, processes, formulas and
know-how owned by Licensor as of the date of this Agreement and relating to the Peptides.

          1.10 “Territory” means geographic territories as listed in Exhibit C, without
limitation to marketing channel or class of trade.

     2. License Grant. Subject to all the terms and limitations of this Agreement, Licensor
hereby grants Licensee a license under its Proprietary Rights in the Technology. The license is
limited to and may be exercised solely for the purposes of: (i) performing evaluation and testing
of the Peptide to determine suitability as a functional ingredient in Products, including without
limitation toxicity and effectiveness tests and trials; (ii) making Products; and (iii) marketing
(including selling and offering to sell) Products to distribution customers and end consumers, in
each case solely in the Territory. Licensee will not market pure Peptide or sublicense rights
hereunder with respect to Peptide, but may sell Products at wholesale to other marketers within the
Territory and may combine two or more Peptides into a Product for marketing under this license.

     3. License Scope. Licensee’s license is non-exclusive. Licensee may grant rights by
way of sublicense through wholesale sales of Product to distribution customers to permit those
customers to market Product (but not to market or otherwise distribute the Peptides other than as
incorporated into Product); provided that each such Product customer is bound to all the
limitations and restrictions on Licensee hereunder. Licensee shall give notice to Licensor promptly
upon any such wholesale sale to a third party hereunder. No such grant of rights to a wholesale
customer of Licensee may be further sublicensed; Product sold by Licensee on a wholesale basis may
only be sold directly or through Affiliates of that wholesale customer to end consumers within the
Territory. Notwithstanding the restrictions on sublicensing set forth in this Section 3, Licensee
may extend the licenses granted above to

2

 

its Affiliates (for so long as they remain Affiliates), provided that all such Affiliates
become bound in writing (for Licensor’s benefit) to Licensee’s obligations under this Agreement,
that Licensee assumes full responsibility for compliance by such Affiliates with such obligations,
and that all payments and reports from Affiliates will be made through Licensee together with
Licensee’s payments and reports.

     4. Transfer of Technology. To carry out the physical transfer of Peptides to Licensee,
Licensee will have the right to purchase, at Licensee’s expense, the Peptides from a manufacturer
approved in advance by Licensor, such approval not to be unreasonably withheld. Licensee may also
purchase the Peptides from Licensor, at Licensee’s expense, subject to availability and on terms as
may be agreed between Licensee and Licensor.

     5. Improvements. Any modifications or improvements to or on the Peptides or Technology
(whether or not patentable or copyrightable) that either party develops shall be owned solely by
Licensor. Licensor shall have the right, at its own expense and solely in its own name, to apply
for, prosecute and defend its Proprietary Rights with respect thereto. Licensor’s existing relevant
patents and patent applications in the Territory are listed on Exhibit A. Licensee will
promptly disclose to Licensor and hereby assigns to Licensor any modifications or improvements to
or on the Peptides or Technology that may be made by or for Licensee (the “Licensee
Improvements”) (provided that this provision will not be deemed to grant to Licensee any right
or license not expressly granted herein, including, without limitation, any right to disclose
Proprietary Information of Licensor). Licensor hereby grants back to Licensee a worldwide,
royalty-free, non-exclusive, sublicensable license to fully exploit the Licensee Improvements.
Licensee shall not license or otherwise grant rights in any modifications or improvements derived
from or based on any Licensor Proprietary Information to third parties.

     6. Marketing Efforts. Licensee will use best commercial efforts to successfully market
the Products under its license on a continuous basis. As part of such efforts, but without
limitation, Licensee will spend the money, dedicate the people and resources and perform the
promotional and other obligations specified in Exhibit D.

     7. Marks and Marking. Except to the extent otherwise decided by Licensor, all
promotional materials and packaging of Licensee relating to the subject matter of this Agreement
will include (in easily readable, non-obscured type that is of reasonable size in light of the
other names and notices) any reasonable patent, patent application or other proprietary markings
and notices of Licensor or its licensors. Licensor will have the right of prior approval with
respect to any promotional materials, packaging or statements regarding the Peptides and Products,
and the use of any mark, name, or designation of Licensor. Except as expressly provided herein, (i)
Licensee will not use or register any mark, name, or designation of Licensor or its licensors
anywhere in the world and (ii) Licensee has no right or license with respect to any mark, name, or
designation of or used by Licensor. Use of any Licensor mark and any related goodwill will inure to
Licensor’s benefit.

     8. Royalties; Audit.

          8.1
Licensee will pay Licensor a royalty of ***%.

          8.2 Royalties will be paid within 30 days of the end of each month with respect to
royalty-bearing sales occurring in that month, and will be accompanied by a statement indicating
the associated *** and royalties payable (including currency conversions), itemized by
Product. At Licensor’s request, Licensee will also provide to Licensor records of Licensee (and its
Affiliates, as applicable) that fairly reflect the *** attributable to a particular month.
Royalties shall be paid by Licensee in U.S. dollars from a location in the U.S., with currency
conversions calculated based upon the applicable closing exchange rates quoted by the Citigroup
foreign exchange desk on the last business day

* * * Confidential treatment requested

3

 

of the applicable month. Any amount payable hereunder that is not paid on the date that it
becomes due will bear interest, calculated based on the number of days such payment is late and
compounded monthly, at a rate of the lesser of (i) 1% per month or (ii) the maximum rate permitted
by applicable law.

          8.3 Licensee and its Affiliates shall keep and maintain detailed and accurate books and
records with regard to *** and the calculation thereof, except to the extent that Licensor is
responsible for keeping and maintaining such records pursuant to the Management Agreement. Licensor
or its representatives (or, at Licensor’s option, a reputable independent certified public
accounting firm selected by Licensor) shall be entitled to review and audit such books and records
from time to time, but no more than once per year, during normal business hours upon reasonable
notice to Licensee and at Licensor’s expense; provided that Licensee will bear any such expense if
the review or audit shows an underpayment of more than 5% for any calendar month or in the
aggregate.

          8.4 At Licensor’s request, the parties agree to discuss, via teleconference or other
agreed-upon means, progress under this Agreement (such request not to be made for more than
discussion per month during the term hereof), in connection with which Licensee shall: (i) describe
any evaluation, testing, and commercialization activities with respect to the Products and any
other work relating to the Peptides and Products that it has performed, or caused to be performed,
since the last such report; (ii) evaluate the work performed in relation to the goals of this
Agreement and Licensee’s work plans; and (iii) provide such other information as may be required by
this Agreement or reasonably requested by Licensor.

     9. No Restriction on Competition. Nothing in this Agreement shall be deemed to
prohibit Licensee from developing, making, using, marketing or otherwise distributing or promoting
products competitive with Products produced hereunder, provided that Licensee does not breach any
provision of this Agreement (including, without limitation, Section 10 (Confidentiality)) or
disparage the Peptides or any Products produced hereunder.

     10. Confidentiality. Each party recognizes the importance to the other of the other’s
Proprietary Information. In particular Licensee recognizes that the Peptides and Technology and
other of Licensor’s Proprietary Information (and the confidential nature thereof) are critical to
the business of Licensor and that Licensor would not enter into this Agreement without assurance
that such technology and information and the value thereof will be protected as provided in this
Section 10 and elsewhere in this Agreement. Likewise, Licensor recognizes that the product
formulation and marketing methods of Licensee are valuable trades secrets of Licensee and are
critical to the business of Licensee and that Licensee would not enter into this Agreement or the
Management Agreement without assurance that such technology and information and the value thereof
will be protected as provided in this Section 10 and elsewhere in this Agreement.

     Accordingly, each party agrees as follows:

          10.1 The Receiving Party agrees: (i) to hold the Disclosing Party’s Proprietary Information in
confidence and to take reasonable precautions to protect such Proprietary Information (including,
without limitation, all precautions the Receiving Party employs with respect to its confidential
materials); (ii) not to divulge (except pursuant to a sublicense expressly authorized in this
Agreement) any such Proprietary Information or any information derived therefrom to any third
person; (iii) not to make any use whatsoever at any time of such Proprietary Information except as
expressly authorized in this Agreement or the Management Agreement; and (iv) not to remove or
export from the United States or reexport any such Proprietary Information or any direct product
thereof (e.g., Peptides, or Products by whomever made) except in compliance with and with all
licenses and approvals required under applicable U.S. and foreign export laws and regulations,
including without limitation, those of the U.S. Department

* * * Confidential treatment requested

4

 

of Commerce. Any employee given access to any such Proprietary Information must have a
legitimate “need to know” and shall be similarly bound in writing.

          10.2 Without granting any right or license, the Disclosing Party agrees that clauses (i), (ii)
and (iii) of Section 10.1 shall not apply with respect to information the Receiving Party can
document: (i) is in or (through no improper action or inaction by the Receiving Party or any
Affiliate, agent or employee) enters the public domain (and is readily available without
substantial effort); or (ii) was rightfully in its possession or known by it prior to receipt from
the Disclosing Party; or (iii) was rightfully disclosed to it by another person without
restriction; or (iv) was independently developed by it by persons without access to such
information and without use of any Proprietary Information of the Disclosing Party. The Receiving
Party must promptly notify the Disclosing Party of any information it believes comes within any
circumstance listed in the immediately preceding sentence and will bear the burden of proving the
existence of any such circumstance by clear and convincing evidence. In addition, the Receiving
Party may make disclosures required by law, provided that the Receiving Party gives the Disclosing
Party prompt written notice of such requirement prior to such disclosure, uses reasonable efforts
to limit disclosure and to obtain confidential treatment or a protective order, and has allowed the
Disclosing Party to participate in the proceeding. Each party’s obligations under Section 10.1 will
apply only to disclosures made during the term of this Agreement; however, such obligations will
continue indefinitely with respect to disclosures made during that period. The obligations under
Section 10.1 will not apply to actions of Licensor in performance of its obligations under the
Management Agreement.

          10.3 Immediately upon termination of this Agreement, the Receiving Party will turn over to the
Disclosing Party all Proprietary Information of the Disclosing Party and all documents or media
containing any such Proprietary Information and any and all copies or extracts thereof, except as
may otherwise be provided in the Management Agreement or modifications or amendments thereto.

          10.4 The Receiving Party acknowledges and agrees that due to the unique nature of the
Disclosing Party’s Proprietary Information, there can be no adequate remedy at law for any breach
of its obligations hereunder, that any such breach may allow the Receiving Party or third parties
to unfairly compete with the Disclosing Party resulting in irreparable harm to the Disclosing
Party, and therefore, that upon any such breach or any threat thereof, the Disclosing Party shall
be entitled to appropriate equitable relief (without the posting of any bond) in addition to
whatever remedies it might have at law and to be indemnified by the Receiving Party from any loss
or harm, including, without limitation, lost profits and attorney’s fees, in connection with any
breach or enforcement of the Receiving Party’s obligations hereunder or the unauthorized use or
release of any such Proprietary Information. The Receiving Party will notify the Disclosing Party
in writing immediately upon the occurrence of any such unauthorized release or other breach. Any
breach of this Section 10 will constitute a material breach of this Agreement.

     11. Patent Matters.

          11.1 Licensor retains the sole right and discretion to file and prosecute patent applications
and maintain patents in the Territory relating to the Peptides and Technology and any improvements
made by Licensor.

          11.2 If Licensee becomes aware of any product or activity of any third party that may involve
infringement or violation of any Licensor patent or other Proprietary Right in the Territory, then
Licensee shall promptly notify Licensor in writing of such actual or potential infringement or
violation. Licensor may in its discretion take or not take whatever action it believes is
appropriate in response to any actual or potential infringement or violation of a Licensor patent
or other Proprietary Right; if Licensor

5

 

elects to take action, Licensee will fully cooperate therewith at Licensor’s expense,
including joining as a party if necessary.

          11.3 If Licensor initiates and prosecutes any action under Section 11.2, all legal expense
(including court costs and attorneys’ fees) shall be borne by Licensor and Licensor shall be
entitled to all amounts awarded by way of judgment, settlement or compromise.

          11.4 Licensee understands that Licensor has not conducted comprehensive patent searches in the
Territory. Licensor and Licensee agree to work cooperatively regarding issues concerning patents
and Proprietary Rights and similar matters and to exercise reasonable business judgment in carrying
out the objectives of this Agreement to avoid exposing either party to liability under patent or
similar laws in the Territory. Each party represents and warrants that it is not aware of
infringement or potential infringement issues that have not been communicated to the other in
writing before execution of this Agreement.

     12. Term and Termination.

          12.1 This Agreement will remain in effect for 5 years from the date first set forth above
unless terminated pursuant to Section 12.2. This Agreement will automatically renew for successive
one-year terms unless either party provides notice of termination to the other party at least 60
days before the end of the then-current term.

          12.2 If a party materially breaches a material provision of this Agreement, the other party
hereto may terminate this Agreement upon 30 days’ notice (or 10 days’ notice in the case of
nonpayment) unless the breach is cured within the notice period. If Licensor materially breaches a
material provision of the DermaVentures LLC Agreement or the Management Agreement, Licensee may
terminate this Agreement, subject to the notice and cure provision set forth above in this Section
12.2. If either Licensee or RMS materially breaches a material provision of the DermaVentures LLC
Agreement or the Management Agreement, Licensor may terminate this Agreement upon 30 days’ notice
to Licensee and the breaching entity (or 10 days’ notice in the case of nonpayment) unless the
breach is cured within the notice period.

          12.3 In the event of any termination of this Agreement, all the rights and licenses granted
Licensee under this Agreement and Licensee’s obligation under Section 6 shall terminate and
Licensor’s obligations to negotiate or provide goods, services, facilities, technology or
information shall cease but all other provisions of this Agreement will continue in accordance with
their terms. A sublicense will survive termination and continue according to its terms provided
that: (i) it was properly granted; (ii) Licensor will have no obligation thereunder except to
permit Licensee to continue to obtain the Peptides from an approved manufacturer to the extent
necessary to manufacture the Product that it is obligated to deliver pursuant to the surviving
sublicense; (iii) all the restrictions and limitations of this Agreement shall apply to the
sublicensee as though this Agreement continued in effect; (iv) Licensor shall receive all
consideration due in connection with the sublicense; and (v) in addition to any termination rights
under the sublicense agreement, Licensor shall be entitled to terminate such sublicense on the same
basis as is provided herein for termination of this Agreement. Except in the case of a termination
by Licensor pursuant to Section 12.2, Licensee will have one year to sell Products in its inventory
as of the date of termination, provided that the terms of the preceding sentence shall apply to
such sublicenses by Licensee.

          12.4 Neither party shall incur any liability whatsoever for any damage, loss or expenses of
any kind suffered or incurred by the other arising from or incident to any termination of this

6

 

Agreement (or any part thereof) by such party which complies with the terms of the Agreement
whether or not such party is aware of any such damage, loss or expenses.

          12.5 Termination is not the sole remedy under this Agreement and, whether or not termination
is effected, all other remedies will remain available.

     13. INCIDENTAL AND CONSEQUENTIAL DAMAGES. NOTWITHSTANDING ANYTHING ELSE IN THIS
AGREEMENT OR OTHERWISE, NEITHER PARTY WILL BE LIABLE UNDER ANY CONTRACT, NEGLIGENCE, STRICT
LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES WITH
RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT. THE LIMITATIONS IN THIS SECTION 13 SHALL NOT APPLY
TO BREACHES OF SECTION 10 (CONFIDENTIALITY) OR TO ACTIONS OF LICENSEE BEYOND THE SCOPE OF THE
LICENSE GRANT HEREUNDER. THIS SECTION DOES NOT LIMIT LIABILITY FOR BODILY INJURY OF A PERSON.

     14. LIMITATION OF OBLIGATIONS AND LIABILITY. NOTWITHSTANDING ANYTHING ELSE IN THIS
AGREEMENT OR OTHERWISE, NEITHER LICENSOR NOR LICENSEE WILL BE LIABLE WITH RESPECT TO ANY SUBJECT
MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER THEORY FOR COST
OF PROCUREMENT OF SUBSTITUTE GOODS, SERVICES, TECHNOLOGY OR RIGHTS OR FOR ANY AMOUNTS AGGREGATING
IN EXCESS OF AMOUNTS PAID TO LICENSOR HEREUNDER IN THE 12-MONTH PERIOD BEFORE THE CAUSE OF ACTION
AROSE. THIS SECTION DOES NOT LIMIT LIABILITY (A) FOR BODILY INJURY OF A PERSON OR FOR ACTS OF GROSS
NEGLIGENCE OR BAD FAITH BY EITHER PARTY OR (B) IN THE EVENT AND TO THE EXTENT OF ANY BREACH BY
LICENSEE OF SECTION 2 OR SECTION 3 HEREOF.

     15. Insurance.

          15.1 During the term of this Agreement, each party shall maintain commercial general liability
insurance in amounts not less than $ *** per occurrence and $ *** annual aggregate from
an underwriter who has an A.M. Best rating of A-VII or better, and naming the other party as an
additional insured. Such commercial general liability insurance shall include but not be limited to
contractual and product liability coverage. The general liability insurance shall include worldwide
coverage. The liability policies required under this Section 15 shall be written as primary and
non-contributing to not in excess of any coverage the other party may choose to maintain. The
minimum amounts of insurance coverage required under this Section 15 shall not be construed to
create a limit of a party’s liability hereunder.

          15.2 Each party shall provide the other party with written evidence of such insurance at any
time during the term of this Agreement promptly upon the request of the other party. Each party
shall provide the other party with written notice at least 15 days prior to any cancellation,
non-renewal or material change in such insurance. If a party does not obtain replacement insurance
providing comparable coverage prior to the expiration of such 15-day period, the other party shall
have the right to terminate this Agreement effective at the end of such 15-day period without any
additional waiting periods.

          15.3 Each party shall maintain such commercial general liability insurance beyond the
expiration or termination of this Agreement during the period that any Products are commercially
marketed, distributed or sold under this Agreement.

* * * Confidential treatment requested

7

 

     16. Export Control. Licensee shall comply with and shall, at Licensor’s request,
demonstrate such compliance with, the U.S. Foreign Corrupt Practices Act and all applicable export
laws, restrictions, and regulations of any U.S. or foreign agency or authority, and shall obtain,
and bear all expenses relating to, any necessary licenses and/or exemptions with respect to the
export from the U.S. or elsewhere by Licensee or its agents of any Products (or any set or system
or containing Products) or any Technology or other technology or information it obtains or learns
pursuant to this Agreement (or any direct product thereof).

     17. Independent Contractors. The parties are independent contractors for purposes of
this Agreement and neither has any right or authority to bind the other in any way, except as
provided in the Management Agreement.

     18. Assignment. The rights and obligations of the parties under this Agreement may not
be assigned or transferred without the consent of the other party (and any attempt to do so will be
void), except that: (i) rights to payment of money may be assigned; and (ii) this Agreement and the
rights and obligations hereunder may be assigned by Licensor to an acquiror of all or substantially
all of its assets, business or capital stock. For purposes of this Section 18, any change in the
ownership of, or power to vote, a majority of the outstanding equity interests in Licensee, any
sale, lease, distribution or other disposition of all or substantially all of Licensee’s assets, or
any dissolution or termination of Licensee, shall in each case constitute an assignment of the
rights and obligations of Licensee hereunder.

     19. WARRANTY DISCLAIMER. EXCEPT AS EXPRESSLY PROVIDED IN SECTION 11, LICENSOR MAKES NO
WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS
AGREEMENT AND HEREBY DISCLAIMS WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
NONINFRINGEMENT WITH RESPECT TO ANY AND ALL OF THE FOREGOING.

     20. Miscellaneous.

          20.1 Amendment and Waiver. Except as otherwise expressly provided herein, any
provision of this Agreement may be amended and the observance of any provision of this Agreement
may be waived (either generally or any particular instance and either retroactively or
prospectively) only with the written consent of the parties.

          20.2 Governing Law; Legal Actions; Attorneys’ Fees. This Agreement shall be governed
by and construed under the laws of the State of Washington and the United States without regard to
conflicts of laws provisions thereof and without regard to the United Nations Convention on
Contracts for the International Sale of Goods. Jurisdiction and venue for actions related to the
subject matter hereof shall lie in the state and federal courts located in King County, Washington
and Cook County, Illinois only. Both parties consent to the jurisdiction of such courts and agree
that process may be served in the manner provided herein for giving of notices or otherwise as
allowed by Washington or Illinois or U.S. federal law. In any action or proceeding to enforce
rights under this Agreement, the prevailing party shall be entitled to recover its reasonable costs
and attorneys’ fees.

          20.3 Headings. Headings and captions are for convenience only and are not to be used
in the interpretation of this Agreement.

          20.4 Notices. All notices, requests, and other communications hereunder shall be in
writing. Any notice, request, or other communication hereunder shall be deemed duly given: (a) when
delivered personally to the recipient; (b) 1 business day after being sent to the recipient by
reputable overnight courier service (charges prepaid); (c) 1 business day after being sent to the
recipient by fax or

8

 

email; or (d) 4 business days after being mailed to the recipient by certified or registered
mail, return receipt requested and postage prepaid, and addressed to the intended recipient as set
forth below:

	 	 	 	 	 	 	 
	If to Licensee:	 	If to Licensor:
	 
	 	 	 	 	 	 
	Address:

	 	440 S. LaSalle St., Suite 3400
Chicago, IL 60605
	 	Address:
	 	22118
20th Ave.
SE Suite 204
Bothell, WA 98021
	 
	 	 	 	 	 	 
	Fax:

	 	***
	 	Fax:
	 	(425) 806-2999
	Email:

	 	***
	 	Email:
	 	***
	Attn:

	 	***
	 	Attn:
	 	***

Either party may change the address or other contact information to which notices, requests, and
other communications hereunder are to be delivered by giving the other party notice in the manner
set forth herein.

          20.5 Entire Agreement. This Agreement, the DermaVentures LLC Agreement, the Management
Agreement, and any agreements, exhibits or schedules referenced or attached hereto and thereto
constitute the entire agreement between the parties with respect to the subject matter hereof and
thereof and shall supersede all prior written and oral and all contemporaneous oral agreements and
understandings with respect to the subject matter hereof and thereof. In the event of any conflict
between this Agreement and the DermaVentures LLC Agreement, this Agreement shall prevail.

          20.6 Force Majeure. Neither party hereto shall be responsible for any failure to
perform its obligations under this Agreement (other than obligations to pay money or obligations
under Section 10 (Confidentiality)) if such failure is caused by acts of God, war, strikes,
revolutions, lack or failure of transportation facilities, laws or governmental regulations or
other causes that are beyond the reasonable control of such party. Obligations hereunder, however,
shall in no event be excused but shall be suspended only until the cessation of any cause of such
failure. In the event that such force majeure should obstruct performance of this Agreement for
more than six (6) months, the parties hereto shall consult with each other to determine whether
this Agreement should be modified. The party facing an event of force majeure shall use diligent
commercial efforts in order to remedy that situation as well as to minimize its effects. A case of
force majeure shall be notified to the other party within 5 days after its occurrence.

          20.7 Severability. If any provision of this Agreement is held illegal, invalid or
unenforceable by a court of competent jurisdiction, that provision will be limited or eliminated to
the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect
and enforceable.

          20.8 No Implied License. Each party recognizes that Licensor grants no license, by
implication or otherwise, except for the licenses expressly set forth in this Agreement.

          20.9 Basis of Bargain. Each party recognizes and agrees that the warranty disclaimers
and liability and remedy limitations in this Agreement are material bargained for bases of this
Agreement

* * * Confidential treatment requested

9

 

and that they have been taken into account and reflected in determining the consideration to
be given by each party under this Agreement and in the decision by each party to enter into this
Agreement.

[Signature page follows]

10

 

     The parties have entered into this Agreement as of the date first written above.

	 	 	 
	LICENSEE:

	 	LICENSOR:
	DERMAVENTURES, LLC

	 	HELIX BIOMEDIX, INC.
	 
	 	 
	By:
RMS Group, LLC, its  sole Manager

	 	 
	 
	 	 
	By:
BKB Partners, LLC, its  sole Manager

	 	 
	 
	 	 
	By: /s/ Ralph Katz

	 	By: /s/ R. Stephen Beatty
	Name: Ralph Katz

	 	Name: R. Stephen Beatty
	Title: Manager

	 	Title: President and Chief Executive Officer

 

 

EXHIBIT A

PEPTIDES, PATENTS AND PATENT APPLICATIONS

Peptides

	 	 	 	 	 
	Name	 	P-No.	 	Primary Sequence
	***

	 	***
	 	***

Patents and Patent Applications

	 	***	 	 
	 

* * * Confidential treatment requested

 

 

EXHIBIT B

PRODUCTS AND SETS / SYSTEMS CONTAINING PEPTIDES

	A.	 	P.A.C. Perfect (Peptide-powered Acne Control) Treatment
Essence — [***]

     P.A.C. Perfect Treatment
Essence may be marketed as part of a set containing the following additional products
not containing any Peptide: [***] (the “P.A.C. Perfect Set”). ***.

* * * Confidential treatment requested

 

 

EXHIBIT C

TERRITORY

North America

Central America

 

 

EXHIBIT D

MARKETING AND ADVERTISING PERFORMANCE COMMITMENTS

Licensee commits to investing at
least $ *** in marketing and advertising by September 30, 2008 and each year thereafter with any
investment beyond $ *** in a given year being credited to the next year. This effort includes, but
is not limited to advertising production costs, advertising expenditures, website marketing,
call center sales support, and fulfillment center customer service support. In the event, that
Licencee determines it must re-make the advertising production, it can request an additional 90
days. In the event that Licensee changes its marketing strategy, parties can, by mutual agreement,
changes the Licensee’s performance commitment to a minimum sales commitment.

* * * Confidential treatment requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]